Literature DB >> 26281945

Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Delinda A Johnson1, Jeffrey A Johnson2.   

Abstract

The brain is very sensitive to changes in redox status; thus maintaining redox homeostasis in the brain is critical for the prevention of accumulating oxidative damage. Aging is the primary risk factor for developing neurodegenerative diseases. In addition to age, genetic and environmental risk factors have also been associated with disease development. The primary reactive insults associated with the aging process are a result of oxidative stress (OS) and nitrosative stress (NS). Markers of increased oxidative stress, protein and DNA modification, inflammation, and dysfunctional proteostasis have all been implicated in contributing to the progression of neurodegeneration. The ability of the cell to combat OS/NS and maintain a clearance mechanism for misfolded aggregating proteins determines whether or not it will survive. A critical pathway in this regard is the Nrf2 (nuclear factor erythroid 2-related factor 2)- antioxidant response element (ARE) pathway. Nrf2 activation has been shown to mitigate a number of pathologic mechanisms associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis. This review will focus on the role of Nrf2 in these diseases and the potential for Nrf2 activation to attenuate disease progression.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyotrophic lateral sclerosis; Huntington’s disease; Multiple sclerosis; Nrf2; Oxidative stress; Parkinson’s disease

Mesh:

Substances:

Year:  2015        PMID: 26281945      PMCID: PMC4809057          DOI: 10.1016/j.freeradbiomed.2015.07.147

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  223 in total

1.  Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid.

Authors:  M A Lovell; W R Markesbery
Journal:  Arch Neurol       Date:  2001-03

2.  Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element.

Authors:  Andrew D Kraft; Jong-Min Lee; Delinda A Johnson; Yuet Wai Kan; Jeffrey A Johnson
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

3.  Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.

Authors:  Marcus J Calkins; Rebekah J Jakel; Delinda A Johnson; Kaimin Chan; Yuet Wai Kan; Jeffrey A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

4.  Microglial activation and chronic neurodegeneration.

Authors:  Melinda E Lull; Michelle L Block
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

5.  Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.

Authors:  Marcus J Calkins; Jessica A Townsend; Delinda A Johnson; Jeffrey A Johnson
Journal:  Exp Neurol       Date:  2010-04-18       Impact factor: 5.330

6.  2014 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-03       Impact factor: 21.566

7.  Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.

Authors:  Scott A Reisman; Chun-Yue I Lee; Colin J Meyer; Joel W Proksch; Keith W Ward
Journal:  Arch Dermatol Res       Date:  2013-12-22       Impact factor: 3.017

Review 8.  Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis.

Authors:  Kalavathi Dasuri; Le Zhang; Jeffrey N Keller
Journal:  Free Radic Biol Med       Date:  2012-09-19       Impact factor: 7.376

9.  Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients.

Authors:  W A Pedersen; W Fu; J N Keller; W R Markesbery; S Appel; R G Smith; E Kasarskis; M P Mattson
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

10.  Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis.

Authors:  Tej K Pareek; Abdelmadjid Belkadi; Sashi Kesavapany; Anita Zaremba; Sook L Loh; Lianhua Bai; Mark L Cohen; Colin Meyer; Karen T Liby; Robert H Miller; Michael B Sporn; John J Letterio
Journal:  Sci Rep       Date:  2011-12-19       Impact factor: 4.379

View more
  110 in total

1.  Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.

Authors:  Fatma H Al-Awadhi; Lilibeth A Salvador-Reyes; Lobna A Elsadek; Ranjala Ratnayake; Qi-Yin Chen; Hendrik Luesch
Journal:  ACS Chem Neurosci       Date:  2020-06-19       Impact factor: 4.418

Review 2.  Nutritional strategies to optimise cognitive function in the aging brain.

Authors:  Devin Wahl; Victoria C Cogger; Samantha M Solon-Biet; Rosilene V R Waern; Rahul Gokarn; Tamara Pulpitel; Rafael de Cabo; Mark P Mattson; David Raubenheimer; Stephen J Simpson; David G Le Couteur
Journal:  Ageing Res Rev       Date:  2016-06-26       Impact factor: 10.895

Review 3.  Small molecules inhibiting Keap1-Nrf2 protein-protein interactions: a novel approach to activate Nrf2 function.

Authors:  Chunlin Zhuang; Zhongli Wu; Chengguo Xing; Zhenyuan Miao
Journal:  Medchemcomm       Date:  2016-11-17       Impact factor: 3.597

Review 4.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

5.  Effects of the Nrf2 Protein Modulator Salvianolic Acid A Alone or Combined with Metformin on Diabetes-associated Macrovascular and Renal Injury.

Authors:  Ping Wu; Yu Yan; Lin-Lin Ma; Bi-Yu Hou; Yang-Yang He; Li Zhang; Zi-Ran Niu; Jun-Ke Song; Xiao-Cong Pang; Xiu-Ying Yang; Guan-Hua Du
Journal:  J Biol Chem       Date:  2016-07-14       Impact factor: 5.157

6.  Characterization of Detergent Insoluble Proteome in Chronic Traumatic Encephalopathy.

Authors:  Jonathan D Cherry; Ahmad Zeineddin; Eric B Dammer; James A Webster; Duc Duong; Nicholas T Seyfried; Allan I Levey; Victor E Alvarez; Bertrand R Huber; Thor D Stein; Patrick T Kiernan; Ann C McKee; James J Lah; Chadwick M Hales
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

7.  Conjugated linoleic acid prevents age-dependent neurodegeneration in a mouse model of neuropsychiatric lupus via the activation of an adaptive response.

Authors:  Antonio Monaco; Ida Ferrandino; Floriana Boscaino; Ennio Cocca; Luisa Cigliano; Francesco Maurano; Diomira Luongo; Maria Stefania Spagnuolo; Mauro Rossi; Paolo Bergamo
Journal:  J Lipid Res       Date:  2017-11-22       Impact factor: 5.922

8.  Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Eric Ferreira; Thuy-Vi Nguyen; Kristian Doyle; Antonella Caccamo; Salvatore Oddo
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

9.  Neuroprotective Effects of Kinetin Against Glutamate-Induced Oxidative Cytotoxicity in HT22 Cells: Involvement of Nrf2 and Heme Oxygenase-1.

Authors:  Yunpeng Wei; Dan Liu; Yin Zheng; Chaoshuang Hao; Honglian Li; Wuqing Ouyang
Journal:  Neurotox Res       Date:  2017-09-12       Impact factor: 3.911

10.  Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption.

Authors:  Priscila S Souza; Elaine D Gonçalves; Giulia S Pedroso; Hemelin R Farias; Stella C Junqueira; Rodrigo Marcon; Talita Tuon; Maíra Cola; Paulo C L Silveira; Adair R Santos; João B Calixto; Cláudio T Souza; Ricardo A de Pinho; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2016-07-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.